An Open label, balanced, randomized, multiple-dose two-period, two-treatment, two-sequence, steady state, crossover comparative bioequivalence study of two formulations of Azathioprine in adult patients with Rheumatoid Arthritis (RA)

Orion Pharma0 个研究点目标入组 42 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 已完成
发起方: Orion Pharma
入组人数: 42

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•Inclusion Criteria:
•1.Adult patients, either sex, aged between 18 and 55 years (both inclusive) with acceptable BMI.
•2.RA patients on maintenance therapy with twice daily 50 mg oral Azathioprine with or without a fixed dose (maximum of 30 mg/week) of Methotrexate.
•Having moderate to aggressive disease stage, as per American Rheumatism Association defined by the presence of at least 3 of the following criteria:
•(a) tenderness of more than 6 joints
•(b) swelling of more than 3 joints
•(c) morning stiffness longer than 45 minutes
•(d) articular index greater than 20
•(e) ESR greater than 28 mm/h.
•3.CRP, ANTI-CCP antibodies & RA factor done within 6 months of screening or at screening suggestive of active Rheumatoid arthritis.
•4.Subjects must be off corticosteroids or on a stable dose of corticosteroid for at least 2 weeks prior to enrollment. The maximal daily dose of corticosteroid at Baseline must not exceed the equivalent of 10 mg of prednisone.
•5.Subjects must be free of any clinically significant condition or situation, other than RA that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
•6.Liver and kidney function (ALT /AST/ AP / creatinine < 2 x upper normal limit).
•7.Subject Screening and Baseline clinical laboratory tests (complete blood count [CBC] and blood chemistries) must be within acceptable ranges.
•8.Subjects are willing and able to adhere to the study visit schedule and other protocol requirements as evidenced by a written informed consent.
•9.Women of child-bearing potential and all men must agree to use a medically accepted method of contraception prior to screening, while receiving protocol-specified medication, and for 6 months after stopping the medication. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or injectable hormonal contraceptive, and surgical sterilization (e.g., hysterectomy or tubal ligation).
•10.Female subjects of childbearing potential must have a negative serum pregnancy test (beta-HCG) at Screening.

排除标准

•1.Adult patients with RA on therapy with any other agent apart from twice daily dose of Azathioprine alone or along with use of NSAIDs, fixed low-dose glucocorticoids and/or fixed dose of Methotrexate.
•2.Anemia (hemoglobin < 08 gm %).
•3.Patients with low or absent TPMT activity who are at increased risk.(<5.5 unit).
•4.Bone marrow suppression (platelets / leucocytes < 1 x lower normal level).
•5.Small bowel surgery interfering significantly with resorptive area.
•6.Concomitant use of allopurinol, ACE-inhibitors or furosemide.
•7.Pregnancy, expected pregnancy or lactation within 6 months.
•8.Subjects who have a history of a known allergy/sensitivity to study drug or its excipients.
•9.Subjects who have had serious infections (eg, active hepatitis, pneumonia, or pyelonephritis) within 2 months of screening. Less serious infections (such as acute upper respiratory tract infection [colds] or a simple urinary tract infection) need not be considered as exclusion at the discretion of the investigator.
•10.Subjects who have had a nontuberculous mycobacterial infection or opportunistic infection (eg, cytomegalovirus, Pneumocystis carinii, aspergillosis) within 6 months prior to Screening.
•11.Subjects who have a known infection with human immunodeficiency virus (HIV) and/or hepatitis B or hepatitis C.
•12.Subjects who have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral diseases.
•13.Subjects who have a known history of demyelinating disease suggestive of multiple sclerosis or optic neuritis.
•14.Presence of a transplanted organ (with the exception of a corneal transplant >3 months prior to screening).
•15.Subjects who have a history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
•16.Subjects who have any current known malignancy or malignancy within 5 years prior to screening (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence).
•17.Subjects who have poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
•18.Subjects who have had a known substance abuse or dependency (drug or alcohol) within 3 years of Screening.
•19.Subjects who have other inflammatory diseases that might interfere with the evaluation of the Rheumatoid Arthritis.
•20.Subjects who have a history of latent or active granulomatous infection, including TB, histoplasmosis, or coccidioidomycosis, prior to Screening.
•21.Subjects who have received any specified prohibited treatment more recently than the indicated washout period prior to Screening.
•22.Subjects who are participating in any other clinical study or who have received treatment with any investigational drug or device within 3 months prior Screening.
•23.Subject who is part of the staff or a family member of the staff personnel directly involved with this study.
•24.Any other condition that, in the investigator?s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory information needed to achieve the objectives of the study.
•25.Abnormal baseline find

研究者

发起方

Orion Pharma

相似试验

已完成

不适用

Bioequivalence study of Olaparib Tablets 150 mg

CTRI/2023/01/048868Cipla Limited44

进行中（未招募）

Unknown

Comparative bioavailability study of intravenous Propofol MCT-LCT 1% versus Disoprivan® 1% Emulsion in healthy, adult subjects under fasting conditions.

CTRI/2023/12/060739Baxter Healthcare Corporation

尚未招募

4 期

To Evaluate Oral Bioavailability Efficacy of Co Enzyme Q10 100mg in Healthy Human Adult Subjects

CTRI/2022/10/046730Doctors Best Inc

尚未招募

不适用

Bioavailability study of Amaryl (glimepiride) Tablet 1 mg in healthy, adult, human subjects under fed conditio

CTRI/2022/11/046993Sanofi Healthcare India Private Limited

尚未招募

1 期

Comparative Bioavailability Study of Ketorolac TromethamineSublingual Tablet 10 mg in healthy human subjects

CTRI/2024/05/067180Troikaa Pharmaceuticals Ltd